Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
120.87
-2.25 (-1.83%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 119.29 - 123.64
52 week 71.63 - 131.84
Open 123.14
Vol / Avg. 419,799.00/417,296.00
Mkt cap 2.47B
P/E 10.07
Div/yield     -
EPS 12.00
Shares 20.82M
Beta 1.02
Inst. own 113%
Jun 1, 2016
Ligand Pharmaceuticals Inc at Craig-Hallum Institutional Investor Conference Add to calendar
May 23, 2016
Ligand Pharmaceuticals Inc Annual Shareholders Meeting - 11:30AM EDT - Add to calendar
May 11, 2016
Ligand Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - 2:20PM EDT - Add to calendar
May 4, 2016
Ligand Pharmaceuticals Inc at Deutsche Bank Health Care Conference - 1:30PM EDT - Add to calendar
May 4, 2016
Q1 2016 Ligand Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Mar 14, 2016
Ligand Pharmaceuticals Inc at ROTH Conference
Mar 3, 2016
Ligand Pharmaceuticals Inc at Deutsche Bank Pharma One-on-One Day
Feb 10, 2016
Q4 2015 Ligand Pharmaceuticals Inc Earnings Call
Feb 10, 2016
Q4 2015 Ligand Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 39.86% 354.49%
Operating margin 51.98% 77.20%
EBITD margin - 43.07%
Return on average assets 6.42% 64.38%
Return on average equity 11.36% 155.61%
Employees 21 -
CDP Score - -

Address

11119 N Torrey Pines Rd Ste 200
LA JOLLA, CA 92037-1028
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Matthew E. Korenberg Chief Financial Officer, Vice President - Finance
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 46
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 54
Bio & Compensation  - Reuters
David M. Knott Independent Director
Age: 70
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 43
Bio & Compensation  - Reuters